Status:
WITHDRAWN
Study of Epratuzumab in Systemic Lupus Erythematosus
Lead Sponsor:
UCB Pharma
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments
Eligibility Criteria
Inclusion
- Must have completed SL0003 Alleviate A through 48 weeks
Exclusion
- Development of toxicity to Epratuzumab
- Significant protocol deviations from SL0003 Study.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00382837
Start Date
January 1 2007
Last Update
May 21 2014
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Tucson, Arizona, United States
3
Los Angeles, California, United States
4
Upland, California, United States